CN105866418B - A kind of breast carcinoma three joint inspection diagnostic kit - Google Patents
A kind of breast carcinoma three joint inspection diagnostic kit Download PDFInfo
- Publication number
- CN105866418B CN105866418B CN201610388260.XA CN201610388260A CN105866418B CN 105866418 B CN105866418 B CN 105866418B CN 201610388260 A CN201610388260 A CN 201610388260A CN 105866418 B CN105866418 B CN 105866418B
- Authority
- CN
- China
- Prior art keywords
- breast carcinoma
- diagnostic kit
- joint inspection
- inspection diagnostic
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention belongs to field of biological detection, be specifically related to the breast carcinoma three joint inspection diagnostic kit of a kind of tumour serum mark CA125, HE4 and P her2.The breast carcinoma three joint inspection diagnostic kit that the present invention provides mainly is coated plate, bovine serum albumin, serum dilution, horseradish peroxidase, tetramethyl benzidine, sulphuric acid, negative controls and positive control solution by abzyme target, biotin antibody and forms.The breast carcinoma three joint inspection diagnostic kit that the present invention provides can detect after operative treatment patient or recurrence and the expression of metastatic tumo(u)r CA125, HE4 and p her2 in the patient, and the clinical diagnosis to breast carcinoma is significant；And the breast carcinoma three joint inspection diagnostic kit that the present invention provides can reduce the interference of other materials in serum, is greatly improved the early diagnosis of the Stability and veracity of testing result, beneficially patient with breast cancer and pre-post processing.
Description
Technical field
The invention belongs to field of biological detection, be specifically related to a kind of tumour serum mark CA125, HE4 and P-her2
Breast carcinoma three diagnostic kit.
Background technology
Breast carcinoma is a kind of relatively conventional malignancy disease, is the female malignant disease that sickness rate is the highest, about
Account for the 10%-12% of various malignancy disease.Showing through correlational study, the whole world the most about 1,600,000 people is diagnosed
For breast carcinoma, and there are about 500,000 people every year and die from this disease.And the sickness rate of breast carcinoma just with annual 4% rate delivery
Increasing, patients also begins to rejuvenation, the physical and mental health of serious threat whole world women.Therefore, strengthen breast cancer treatment technology
Research be extremely necessary.
CA125, HE4 and p-her2 have higher expression in breast carcinoma.In recent years, Serum of Cancer Patients CA125,
HE4 and p-her2 level using value in clinical tumor is put into practice has caused increasing concern.The external serum that has is examined
Test agent box is approved for clinic, and CA125, HE4 and p-her2 serum levels and variation tendency thereof can be used as tumor and control
The evaluation of therapeutic effect and prognosis evaluation index.Therefore CA125, HE4 and p-her2 serum levels detects at tumor diagnosis and therapy
In have important using value.
Traditional CA125, HE4 and p-her2 detection, mainly by traumatic tumor tissue biopsy, uses immune group
Change the method such as (IHC) and fluorescence in situ hybridization (FISH), but these methods can not detect after operative treatment patient or recurrence and
Metastatic tumo(u)r CA125, HE4 and p-her2 expression in the patient.Therefore, research and develop out may be used for detect hands
Patient or recurrence and metastatic tumo(u)r CA125, HE4 and p-her2 expression in the patient after art treatment, non-invasive
Breast cancer tumour detection method is still the difficult problem currently needing solution badly.
Chinese patent application 201510038319.8 discloses a kind of TAA immue quantitative detection reagent box, described examination
Agent box be using the vegetable protein of a kind of tumor antigenicity as antigen coated in 96 orifice plates, swollen with in different experimenter's serum
Tumor antibody resists as one, and the goat anti-human antibody of labelling horseradish peroxidase resists as two, uses indirect immunoluminescence to learn a skill
Detection experimenter's serum tumor antibody.
Chinese patent application 201510600309.9 discloses a kind of test kit for detecting Serum HER2 and purposes, institute
Stating test kit and include the anti-HER 2 monoclonal antibody Herceptin of pairing and biotinylated A18, this test kit is to pass through enzyme
Connection immunoabsorption (ELISA) detects the HER2 expression in blood serum of patients with human breast carcinoma, thus reaches to detect breast carcinoma
Purpose.This test kit be a kind of non-invasive, simplicity, rapidly diagnosis and monitoring HER2 positive tumor disease for examining
Survey the detection kit of breast carcinoma.
But, existing Virus monitory test kit can only detect single index, detection during exist susceptiveness and
The defect that specificity is relatively low, greatly limits the promotion and application of the said goods.
Summary of the invention
In order to solve the deficiency of kit for breast cancer of the prior art, present invention aim at providing a kind of mammary gland
Cancer three joint inspection diagnostic kit, compared to existing kit for breast cancer, kit for breast cancer of the present invention has more
High highly sensitive and higher specificity.
The invention provides a kind of breast carcinoma three joint inspection diagnostic kit, be coated including abzyme target, biotin antibody
Plate, bovine serum albumin, serum dilution, horseradish peroxidase, tetramethyl benzidine, sulphuric acid, negative controls and the positive
Comparison liquid；Described ELISA Plate antibody includes anti-CA 125, HE4 and the p-her2 monoclonal antibody being coated in ELISA Plate；Described life
Thing element antibody coating plate includes biotin labeled CA125, HE4 and p-her2 monoclonal antibody being coated on microwell plate.
Further, the preparation method of described abzyme target is: with the PBS that pH is 8.2 by anti-CA 125, HE4
It is diluted to 20-100 μ g/ml with p-her2 monoclonal antibody, is added in 96 hole ELISA Plate by the addition in 100 μ l/ holes, in temperature
Standing overnight under conditions of 2-8 DEG C, then wash with cleaning mixture, described cleaning mixture is to be containing 0.05%Tween-20, pH
The phosphate buffer of 7.4, dries, must be coated with 96 hole ELISA Plate of anti-CA 125, HE4 and p-her2 monoclonal antibody.
Further, described biotin antibody is coated the preparation method of plate and is: by CA125, HE4 and p-her2 monoclonal anti
Body is mixed into line flag with the biotin of activation, and dialysis is removed unconjugated biotin, obtained biotin CA125, HE4, p-her2
Monoclonal antibody；With the PBS that pH is 8.2, CA125, HE4, p-her2 monoclonal antibody is diluted to 20-100 μ g/ml,
It is added in microwell plate by the addition in 100 μ l/ holes, stands overnight under conditions of temperature is 2-8 DEG C, then wash with cleaning mixture
Washing, described cleaning mixture is to be the phosphate buffer of 7.4 containing 0.05%Tween 20, pH, dries, must be coated with biotin
The microwell plate of CA125, HE4 and p-her2 monoclonal antibody.
Further, described serum dilution is composed of the following components:
Insulin human 5-8U/ML, potassium dihydrogen phosphate 2-4g/L, disodium hydrogen phosphate 2-4g/L, sodium sulfate 4-6g/L, sodium chloride
20-24g/L, NaTDC 10-14g/L, EDTA-2K 0.4-0.6g/L, surplus is water.
Further, described serum dilution is composed of the following components:
Insulin human 6U/ML, potassium dihydrogen phosphate 3g/L, disodium hydrogen phosphate 3g/L, sodium sulfate 5g/L, sodium chloride 22g/L, de-
Oxycholic acid sodium 12g/L, EDTA-2K 0.5g/L, surplus is water.
Further, the pH value of described serum dilution is 6.2-6.5.
Further, the pH value of described serum dilution is 6.4.
Further, the concentration of described tetramethyl benzidine is 0.4mg/ml.
Further, the concentration of described sulphuric acid is 2mol/L.
The present invention is on the basis of conventional elisa, by between biotin and horseradish peroxidase
Effect, establish a kind of highly sensitive biotin-enzyme-linked immunologic detecting kit, to measure the oncoprotein treating in test sample
The expression of CA125, HE4 and p-her2.Because biotin is very easily combined with covalent bond, so there being life with the protein such as antibody
Biotin in CA125, HE4, p-her2 monoclonal antibody of thing element labelling is easily and horseradish peroxidase produces reaction, both
Play the effect of multistage amplification, simultaneously because enzyme can occur the work of catalytic action and colour generation when running into corresponding chromogenic substrate
With, thus reach to detect target antigen or the purpose of antibody molecule.The breast carcinoma three joint inspection diagnostic kit using the present invention can
Effectively, stably to measure the content of CA125, HE4 and p-her2 in blood serum of patients with human breast carcinoma, it is highly sensitive, and test repeats
Property is good.
Further, the serum dilution that the present invention provides can effectively reduce to be done by other materials in inspection serum
Disturb, sensitivity and the early stage of stability, beneficially patient with breast cancer of CA125, HE4 and p-her2 detection can be greatly improved
Diagnosis and pre-post processing.
Compared with prior art, the technical scheme that the present invention provides has the advantage that
(1) the breast carcinoma three joint inspection diagnostic kit that the present invention provides can detect after operative treatment patient or recurrence and turn
CA125, HE4 and p-her2 expression in shifting property tumor patient body, the clinical diagnosis to breast carcinoma is significant；
(2) the breast carcinoma three joint inspection diagnostic kit that the present invention provides can reduce the interference of other materials of serum, greatly
The early diagnosis of big raising testing result Stability and veracity, beneficially patient with breast cancer and pre-post processing.
Detailed description of the invention
To further describe the present invention below in detail.It is pointed out that following description is only to application claims
The illustration of the technical scheme of protection, the not any restriction to these technical schemes.Protection scope of the present invention is with appended
The content that claims are recorded is as the criterion.The test method of unreceipted concrete experimental condition in the following example, generally according to often
Rule condition, molecular cloning texts guide (Sambrook J, et al.2008.Molecular Cloning:A Laboratory
Manual, 3rd Ed.) described in condition, or according to the condition proposed by manufacturer.
Embodiment 1, breast carcinoma three joint inspection diagnostic kit
1, the preparation of breast carcinoma three joint inspection diagnostic kit
1.1, the preparation method of abzyme target is:
With the PBS that pH is 8.2, anti-CA 125, HE4 and p-her2 monoclonal antibody are diluted to 60 μ g/ml, press
The addition in 100 μ l/ holes is added in 96 hole ELISA Plate, stands overnight, then wash with cleaning mixture under conditions of temperature is 4 DEG C
Washing, described cleaning mixture is to be the phosphate buffer of 7.4 containing 0.05%Tween 20, pH, dries, must be coated with anti-CA 125,
96 hole ELISA Plate of HE4 and p-her2 monoclonal antibody.
1.2, biotin antibody is coated the preparation method of plate and is:
The biotin of CA125, HE4 and p-her2 monoclonal antibody Yu activation is mixed into line flag, and dialysis is removed and is not tied
The biotin closed, obtains biotin CA125, HE4 and p-her2 monoclonal antibody；With the PBS that pH is 8.2 by CA125,
HE4 and p-her2 monoclonal antibody is diluted to 50 μ g/ml, is added in microwell plate by the addition in 100 μ l/ holes, is 4 DEG C in temperature
Under conditions of stand overnight, then wash with cleaning mixture, described cleaning mixture is to be the phosphorus of 7.4 containing 0.05%Tween 20, pH
Phthalate buffer, dries, must be coated with the microwell plate of biotin CA125, HE4 and p-her2 monoclonal antibody.
1.3, the configuration of serum dilution:
Take insulin human 5-8U/ML, potassium dihydrogen phosphate 2-4g/L, disodium hydrogen phosphate 2-4g/L, sodium sulfate 4-6g/L, chlorination
Sodium 20-24g/L, NaTDC 10-14g/L, EDTA-2K 0.4-0.6g/L, the regulation pH that adds water is 6.2-6.5.
2, the use step of breast carcinoma three joint inspection diagnostic kit:
2.1, sample-adding:
(1) be coated with anti-CA 125,96 hole ELISA Plate of HE4 and p-her2 monoclonal antibody process:
The 96 hole ELISA Plate being coated with anti-CA 125, HE4 and p-her2 monoclonal antibody divide Positive control wells, the moon
Property control wells, testing sample hole and blank well totally four groups of detection holes, Positive control wells adds positive control solution, 100 μ l/ holes,
Adding negative controls, 100 μ l/ holes in negative control hole, add test serum in testing sample hole, 100 μ l/ holes, sample adds
After complete, then every hole adds the bovine serum albumin that concentration is 0.5% and the serum dilution of 50ul amount of 50ul amount, described
Serum dilution is: insulin human 6U/ML, potassium dihydrogen phosphate 3g/L, disodium hydrogen phosphate 3g/L, sodium sulfate 5g/L, sodium chloride
22g/L, NaTDC 12g/L, EDTA-2K 0.5g/L, the regulation pH value that adds water is 6.4；ELISA Plate is added a cover or covers
Film, discards liquid after placing 2h under the conditions of 37 DEG C, washs with cleaning mixture, dries；
(2) biotin CA125, HE4 and p-her2 monoclonal antibody is added:
Each detection hole adds 100 μ l biotin CA125, HE4 and p-her2 monoclonal antibodies, transfers 37 DEG C of conditions
Discard liquid after putting 1h, each detection hole adds 350 μ l cleaning mixture and soaks 2min, dry or pat dry lightly, washing, dry
Action be repeated 3 times；
(3) horseradish peroxidase is added:
Each detection hole adds the horseradish peroxidase of 100 μ l, after placing 1h under the conditions of 37 DEG C, discards liquid, often
Adding 350 μ l cleaning mixture in individual detection hole and soak 2min, dry or pat dry lightly, the action wash, dried is repeated 5 times；
(4) chromogenic substrate is added:
Being sequentially added into a concentration in each detection hole is 0.4mg/ml tetramethyl benzidine, keeps away under the conditions of 37 DEG C
Light, colour developing；
(5) stop buffer is added:
In each detection hole, add 50 μ l stop buffers successively according to the addition sequence of above-mentioned chromogenic substrate, terminate reaction,
Terminate the liquid showing as detecting in hole of reaction by blue fast transition yellowly.
3, result detection:
After adding stop buffer in 15min, the light detecting each detection hole with enzyme connection instrument under the wavelength condition of 450nm is close
Degree OD value, the examination criteria of detection kit is: with the concentration of standard substance as vertical coordinate (or logarithmic coordinates), OD value is abscissa
(or logarithmic coordinates), (optimal equation should be according to regression equation calculation to use curve expert 1.30 software to draw standard curve
R2Value is determined, with R2Value more levels off to 1 preferably), calculate the actual concentrations of sample.Wherein: positive findings criterion such as table 1
Shown in:
Table 1 positive findings criterion
| The concentration of breast cancer tumour mark | |
| CA125(U/ml) | ＞ 10 |
| HE4(pmol/L) | ＞ 10 |
| HCG(IU/mL) | ＞ 5 |
Embodiment 2, the degree of accuracy test of breast carcinoma three joint inspection diagnostic kit
The coefficient of variation CV value of 96 hole ELISA Plate that prepared by the present invention be coated is less than 8%, to same batch and different batches
Detection kit carry out experimental test, in test result shows batch and batch between the CV value of test kit be respectively less than 8%, illustrate originally
The breast carcinoma three joint inspection diagnostic kit of invention has high-accuracy property.
Embodiment 3, the sensitivity test of breast carcinoma three joint inspection diagnostic kit
Use the test solution of CA125, HE4 and p-her2 standard substance preparation variable concentrations, the most as shown in table 2:
CA125, HE4 and p-her2 standard substance test solution of table 2 variable concentrations
As shown in Table 2, the breast carcinoma three joint inspection diagnostic kit using embodiment 1 preparation is tested each concentration test solution and is entered
Row measures, and is detected by microplate reader, and each concentration measures 3 times.
Result shows, the sensitivity of the breast carcinoma three joint inspection diagnostic kit of embodiment 1 preparation is splendid, and CA125's is sensitive
Degree is for < sensitivity of 1U/ml, HE4 is that < sensitivity of 3pmol/L, HCG is < 1IU/mL.
Embodiment 4, the stability test of breast carcinoma three joint inspection diagnostic kit
1, breast carcinoma three joint inspection diagnostic kit embodiment 1 prepared at room temperature places 3,6 and 12 months, then presses
Method according to embodiment 3 carries out sensitivity determination.
2, the comparative example of the present embodiment is as follows:
Comparative example 1: preparation method, with embodiment 1, differs only in, the PBS that the preparation process of abzyme target uses delays
The flat pH value rushing liquid is 8.0.
Comparative example 2: preparation method, with embodiment 1, differs only in, the PBS that the preparation process of abzyme target uses delays
The flat pH value rushing liquid is 8.4.
Comparative example 3: preparation method, with embodiment 1, differs only in, described serum dilution is: insulin human 6U/ML,
Potassium dihydrogen phosphate 3g/L, disodium hydrogen phosphate 3g/L, sodium sulfate 5g/L, sodium chloride 22g/L, NaTDC 12g/L, add water regulation
PH value is 6.4.
Comparative example 4: preparation method, with embodiment 1, differs only in, described serum dilution is: insulin human 6U/ML,
Potassium dihydrogen phosphate 3g/L, disodium hydrogen phosphate 3g/L, sodium sulfate 5g/L, sodium chloride 22g/L, NaTDC 12g/L, EDTA-
2K0.5g/L, the regulation pH value that adds water is 6.0.
Comparative example 5: preparation method, with embodiment 1, differs only in, described serum dilution is: insulin human 6U/ML,
Potassium dihydrogen phosphate 3g/L, disodium hydrogen phosphate 3g/L, sodium sulfate 5g/L, sodium chloride 22g/L, NaTDC 12g/L, EDTA-
2K0.5g/L, the regulation pH value that adds water is 6.8.
3, result of the test
Result of the test is as shown in table 3, table 4 and table 5:
Table 3 breast carcinoma three joint inspection diagnostic kit deposit 3 months after sensitivity results
| Embodiment 1 | Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | Comparative example 5 | |
| CA125(U/ml) | <1 | 1 | 1 | 20 | 10 | 10 |
| HE4(pmol/L) | <3 | 3 | 3 | 12 | 6 | 6 |
| HCG(IU/mL) | <1 | 1 | 1 | 20 | 10 | 10 |
Table 4 breast carcinoma three joint inspection diagnostic kit deposit 6 months after sensitivity results
| Embodiment 1 | Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | Comparative example 5 | |
| CA125(U/ml) | <1 | 10 | 20 | 80 | 20 | 40 |
| HE4(pmol/L) | <3 | 6 | 12 | 48 | 24 | 24 |
| HCG(IU/mL) | <1 | 10 | 10 | 80 | 200 | 40 |
Table 5 breast carcinoma three joint inspection diagnostic kit deposit 12 months after sensitivity results
| Embodiment 1 | Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | Comparative example 5 | |
| CA125(U/ml) | <1 | 40 | 40 | ＞ 80 | 80 | 80 |
| HE4(pmol/L) | <3 | 24 | 48 | ＞ 48 | 48 | ＞ 48 |
| HCG(IU/mL) | <1 | 20 | 20 | ＞ 80 | 80 | 80 |
From table 3, table 4 and table 5, breast carcinoma three joint inspection diagnostic kit prepared by the present invention has preferable sensitive
Degree.
Present invention merely illustrates some claimed specific embodiments, one of them or more skill
Technical characteristic described in art scheme can be combined with arbitrary one or more technical schemes, and these are combined and obtain
Technical scheme also in the application protection domain, combined just as these and the technical scheme that obtains is open in the present invention
In content as concrete record.
Claims (10)
1. a breast carcinoma three joint inspection diagnostic kit, it is characterised in that include abzyme target, biotin antibody be coated plate,
Bovine serum albumin, serum dilution, horseradish peroxidase, tetramethyl benzidine, sulphuric acid, negative controls and positive control
Liquid；Described ELISA Plate antibody includes anti-CA 125, HE4 and the p-her2 monoclonal antibody being coated in ELISA Plate；Described biotin
Antibody coating plate includes biotin labeled CA125, HE4 and p-her2 monoclonal antibody being coated on microwell plate.
2. breast carcinoma three joint inspection diagnostic kit as claimed in claim 1, it is characterised in that the preparation of described abzyme target
Method is:
With the PBS that pH is 8.2, anti-CA 125, HE4 and p-her2 monoclonal antibody are diluted to 20-100 μ g/ml, press
The addition in 100 μ l/ holes is added in 96 hole ELISA Plate, stands overnight, then wash with cleaning mixture under conditions of temperature is 2-8 DEG C
Washing, described cleaning mixture is to be the phosphate buffer of 7.4 containing 0.05%Tween-20, pH, dries, to obtain final product.
3. breast carcinoma three joint inspection diagnostic kit as claimed in claim 1, it is characterised in that described biotin antibody is coated plate
Preparation method be:
The biotin of CA125, HE4 and p-her2 monoclonal antibody Yu activation is mixed into line flag, and dialysis is removed unconjugated
Biotin, obtains biotin CA125, HE4 and p-her2 monoclonal antibody；With the PBS that pH is 8.2 by CA125, HE4 and
P-her2 monoclonal antibody is diluted to 20-100 μ g/ml, is added in microwell plate by the addition in 100 μ l/ holes, is 2-8 in temperature
Standing overnight under conditions of DEG C, then wash with cleaning mixture, described cleaning mixture is to be 7.4 containing 0.05%Tween 20, pH
Phosphate buffer, dries, to obtain final product.
4. breast carcinoma three joint inspection diagnostic kit as claimed in claim 1, it is characterised in that described serum dilution is by following
Component forms:
Insulin human 5-8U/ML, potassium dihydrogen phosphate 2-4g/L, disodium hydrogen phosphate 2-4g/L, sodium sulfate 4-6g/L, sodium chloride 20-
24g/L, NaTDC 10-14g/L, EDTA-2K 0.4-0.6g/L, surplus is water.
5. breast carcinoma three joint inspection diagnostic kit as claimed in claim 4, it is characterised in that described serum dilution is by following
Component forms:
Insulin human 6U/ML, potassium dihydrogen phosphate 3g/L, disodium hydrogen phosphate 3g/L, sodium sulfate 5g/L, sodium chloride 22g/L, deoxidation gallbladder
Acid sodium 12g/L, EDTA-2K 0.5g/L, surplus is water.
6. breast carcinoma three joint inspection diagnostic kit as claimed in claim 4, it is characterised in that the pH value of described serum dilution
For 6.2-6.5.
7. breast carcinoma three joint inspection diagnostic kit as claimed in claim 5, it is characterised in that the pH value of described serum dilution
It is 6.4.
8. breast carcinoma three joint inspection diagnostic kit as claimed in claim 1, it is characterised in that described tetramethyl benzidine dense
Degree is 0.4mg/ml.
9. breast carcinoma three joint inspection diagnostic kit as claimed in claim 1, it is characterised in that the concentration of described sulphuric acid is
2mol/L。
10. breast carcinoma three joint inspection diagnostic kit as claimed in claim 1, it is characterised in that described negative controls is not
Normal human serum containing CA125, HE4 and p-her2, described positive control solution is containing breast cancer tumour mark CA125, HE4
Blood serum of patients with human breast carcinoma with p-her2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610388260.XA CN105866418B (en) | 2016-06-03 | 2016-06-03 | A kind of breast carcinoma three joint inspection diagnostic kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610388260.XA CN105866418B (en) | 2016-06-03 | 2016-06-03 | A kind of breast carcinoma three joint inspection diagnostic kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105866418A CN105866418A (en) | 2016-08-17 |
| CN105866418B true CN105866418B (en) | 2016-11-09 |
Family
ID=56675919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610388260.XA Active CN105866418B (en) | 2016-06-03 | 2016-06-03 | A kind of breast carcinoma three joint inspection diagnostic kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105866418B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106248971B (en) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | For detecting the ELISA kit of HER2 contents, application method and purposes in human serum |
| CN106501529A (en) * | 2016-11-17 | 2017-03-15 | 南京健安医疗科技有限公司 | A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application |
| CN106855575B (en) * | 2016-12-30 | 2019-01-18 | 珠海博美生物科技有限公司 | A kind of three quick detection kit of breast cancer |
| CN109100508A (en) * | 2018-07-09 | 2018-12-28 | 珠海中科先进技术研究院有限公司 | A kind of chronic fatigue syndrome diagnostic kit |
| CN109142744A (en) * | 2018-07-26 | 2019-01-04 | 珠海中科先进技术研究院有限公司 | A kind of autism spectrum disorder diagnostic kit |
| CN109342730A (en) * | 2018-12-07 | 2019-02-15 | 江苏省原子医学研究所 | The test strips of gynecological tumor marker HER-2 and HE4 are detected simultaneously |
| CN109342731A (en) * | 2018-12-07 | 2019-02-15 | 江苏省原子医学研究所 | The kit of gynecological tumor marker HER-2 and HE4 is detected simultaneously |
| CN110716043B (en) * | 2019-10-23 | 2023-02-28 | 郑州大学 | Serum protein marker, kit and detection method for early screening and diagnosis of breast cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520768A (en) * | 2007-03-09 | 2010-06-17 | トライパス イメージング インコーポレイテッド | HE4 monoclonal antibodies and methods for their use |
| CN105158474A (en) * | 2015-09-18 | 2015-12-16 | 安徽省立医院 | Reagent kit for detecting serum HER2 and application |
-
2016
- 2016-06-03 CN CN201610388260.XA patent/CN105866418B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105866418A (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105866418B (en) | A kind of breast carcinoma three joint inspection diagnostic kit | |
| Peng et al. | Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy | |
| CN104316685B (en) | Diacetyl spermine detection kit and preparation method and application thereof | |
| Moran-Jones et al. | Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer | |
| CN205333645U (en) | Lp -PLA2 quick quantitative detection test paper strip in people's serum | |
| CN106855575B (en) | A kind of three quick detection kit of breast cancer | |
| CN105372428B (en) | The immue quantitative detection reagent box of CA125 | |
| CN102445539A (en) | Antibody chip for adopting in early screening and diagnosis of liver cancer, and kit thereof | |
| Tas et al. | Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer | |
| CN112345755A (en) | Biomarker of breast cancer and application thereof | |
| CN107255711B (en) | Osteopontin is used to prepare or screens the purposes of acute-on-chronic liver failure diagnostic reagent | |
| CN104897900B (en) | A kind of Prostasomes leak proteantigen and its antibody and application | |
| Jiang et al. | RICTOR expression in esophageal squamous cell carcinoma and its clinical significance | |
| Tang et al. | Co-Upregulation of 14-3-3ζ and P-Akt is associated with oncogenesis and recurrence of hepatocellular carcinoma | |
| CN110187111B (en) | ELISA kit for screening early cardiac cancer | |
| Kaira et al. | CD98 expression is associated with the grade of malignancy in thymic epithelial tumors | |
| Al-Toubah et al. | Sensitivity and specificity of the NETest: a validation study | |
| CN107167604B (en) | FLOT1 is as the application in oophoroma biomarker | |
| CN108866064A (en) | A kind of aptamer of targeted metastatic human breast cancer cell and its application | |
| WO2020200323A1 (en) | Very early cell marker of gastric cancer and early cell marker of gastric precancerous lesion and application thereof in diagnostic kit | |
| CN105259348B (en) | A kind of secreting type Sema4C albumen and its application | |
| CN109557310B (en) | Marker for judging cancer prognosis and application thereof | |
| CN104360062B (en) | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared | |
| CN109490542A (en) | Colloidal gold detection device of γ synapse nucleoprotein and its preparation method and application | |
| CN107102147B (en) | Application of the THBS2 Protein Detection object in preparation prognosis of HCC assessment kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210428 Address after: 570000 Zone E, Fuxing City Industrial Park, 32 Binhai Avenue, Longhua District, Haikou City, Hainan Province Patentee after: Setes (Hainan) biomedical Co.,Ltd. Address before: 510530, 84, two, science Road, hi tech Industrial Development Zone, Guangdong, Guangzhou Province, 101 Patentee before: GUANGZHOU HUAHONG BIOTECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |